Following Johnson & Johnson, the American pharmaceutical company Eli Lilly on Tuesday interrupted clinical trials of a vaccine and an experimental anti-coronavirus remedy in an attempt to prevent participants from possible side effects. The day before, pharmaceutical giant Johnson & Johnson had suspended its clinical trial of an anti-coronavirus vaccine. These two groups need time to assess the risk of possible side effects in participants in these trials.
By the way, one of the volunteers fell ill under circumstances not yet understood. “We have temporarily halted additional dosing in all of our clinical trials of an investigational vaccine against Covid-19, including the entire phase 3 trial, due to unexplained illness in a participant,” said Johnson & Johnson announced in a press release.
This interruption immediately resulted in the closure of the Internet registration system in order to recruit volunteers for the needs of phase 3 of the trial. And in parallel, the independent commission for the safety of the patients was seized.
The recruitment of participants for phase 3 of the clinical trials of this pharmaceutical group had begun at the end of September with the objective of hiring 60,000 participants in more than 200 sites on American soil. Tests were also taking place in other countries, including Mexico, Brazil and South Africa.